© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 85360 refers to the laboratory test known as euglobulin lysis, which is specifically designed to measure the euglobulin clot lysis time (ECLT). This test evaluates the fibrinolytic activity present in plasma, providing a comprehensive assessment of the fibrin clotting system. It is particularly useful for monitoring patients who are undergoing treatment with streptokinase, a medication that helps dissolve blood clots. The procedure begins with the collection of a blood sample through a venipuncture, which is a separate reportable procedure. To prevent clotting, the whole blood sample is treated with trisodium citrate, an anticoagulant, and is subsequently chilled to maintain its integrity. The process involves centrifugation to separate the plasma, which is then diluted with acetic acid and incubated on ice for a specified duration. This incubation allows for the formation of a precipitate, known as the euglobulin fraction of plasma, which contains critical components such as plasminogen, plasminogen activators (t-PA), and fibrinogen. Following this, the sample undergoes a second centrifugation to collect the precipitate, which is then dissolved in a buffer solution. The final step involves clotting the sample with thrombin and monitoring for clot lysis at 15-minute intervals. It is essential to include a control sample alongside the patient sample to ensure the accuracy and reliability of the test results.
© Copyright 2025 Coding Ahead. All rights reserved.
The euglobulin lysis test (CPT® Code 85360) is indicated for the following conditions:
The procedure for conducting the euglobulin lysis test involves several detailed steps:
After the euglobulin lysis test is completed, the results are analyzed to assess the fibrinolytic activity in the patient's plasma. It is important to interpret the results in conjunction with clinical findings and other laboratory tests. The test may provide valuable information regarding the patient's response to streptokinase therapy and the overall status of their fibrin clotting system. Any abnormal findings should be discussed with the healthcare provider to determine the appropriate next steps in patient management. Additionally, proper documentation of the test results and any relevant clinical information is essential for ongoing patient care and follow-up.
| Short Descr | EUGLOBULIN LYSIS | Medium Descr | EUGLOBULIN LYSIS | Long Descr | Euglobulin lysis | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 233 - Laboratory - Chemistry and Hematology |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| Pre-1990 | Added | Code added. |
Get instant expert-level medical coding assistance.